European Approval for Lung and Skin Cancer Drugs
The European Medicines Agency gave marketing authorization to two cancer therapies in February. Non–Small Cell Lung Cancer The Committee for Medicinal Products for Human Use (CHMP) approved tislelizumab (Tizveni) for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) in adults. Tislelizumab is a humanized immunoglobulin (Ig)–G4 variant monoclonal antibody that aids the body’s immune …
Read More
0
